Tech Company Financing Transactions

Tesaro Funding Round

Tesaro, based in Waltham, secured $101 million in funding from Kleiner Perkins Caufield & Byers, Deerfield Capital and InterWest Partners.

Transaction Overview

Company Name
Tesaro
Announced On
6/21/2011
Transaction Type
Venture Equity
Amount
$101,000,000
Round
Series B
Investors

Kleiner Perkins Caufield & Byers (Lead Investor) (Beth Seidenberg)

Deerfield Capital

InterWest Partners (Arnold Oronsky)

New Enterprise Associates (David Mott)

Pappas Ventures

Proceeds Purpose
TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein; recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1000 Winter St.
Waltham, MA 02451
USA
Phone
(339) 970-0900
Website
www.tesarobio.com
Email Address
[email protected]
Overview
TESARO (NASDAQ: TSRO) is an oncology-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Profile
Tesaro LinkedIn Company Profile
Social Media
Tesaro Company Twitter Account
Company News
Tesaro News
Facebook
Tesaro on Facebook
YouTube
Tesaro on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Lonnie Moulder
  Lonnie Moulder LinkedIn Profile  Lonnie Moulder Twitter Account  Lonnie Moulder News  Lonnie Moulder on Facebook
Chief Financial Officer
Timothy Pearson
  Timothy Pearson LinkedIn Profile  Timothy Pearson Twitter Account  Timothy Pearson News  Timothy Pearson on Facebook
Chief Medical Officer
Martin Huber
  Martin Huber LinkedIn Profile  Martin Huber Twitter Account  Martin Huber News  Martin Huber on Facebook
President
Mary Hedley
  Mary Hedley LinkedIn Profile  Mary Hedley Twitter Account  Mary Hedley News  Mary Hedley on Facebook
Vice President
Orlando Oliveira
  Orlando Oliveira LinkedIn Profile  Orlando Oliveira Twitter Account  Orlando Oliveira News  Orlando Oliveira on Facebook
VP - Bus. Development
Grant Bogle
  Grant Bogle LinkedIn Profile  Grant Bogle Twitter Account  Grant Bogle News  Grant Bogle on Facebook
VP - Bus. Development
Allene Diaz
  Allene Diaz LinkedIn Profile  Allene Diaz Twitter Account  Allene Diaz News  Allene Diaz on Facebook
VP - General Counsel
Joseph Farmer
  Joseph Farmer LinkedIn Profile  Joseph Farmer Twitter Account  Joseph Farmer News  Joseph Farmer on Facebook
VP - Human Resources
Michelle Graham
  Michelle Graham LinkedIn Profile  Michelle Graham Twitter Account  Michelle Graham News  Michelle Graham on Facebook
VP - Operations
William Aitchison
  William Aitchison LinkedIn Profile  William Aitchison Twitter Account  William Aitchison News  William Aitchison on Facebook
VP - Regulatory Affairs
Jennifer Jackson
  Jennifer Jackson LinkedIn Profile  Jennifer Jackson Twitter Account  Jennifer Jackson News  Jennifer Jackson on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/21/2011: Guardian Analytics venture capital transaction
Next: 6/21/2011: Plasmonix venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.